S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00630968|
Recruitment Status : Completed
First Posted : March 7, 2008
Last Update Posted : November 15, 2013
|Condition or disease||Intervention/treatment||Phase|
|Epilepsy||Drug: Levetiracetam (Keppra)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1541 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Trial Studying the Safety and Efficacy of Keppra® as Adjunctive Therapy in Adult Patients With Uncontrolled Partial Epilepsy|
|Study Start Date :||August 2000|
|Actual Primary Completion Date :||February 2004|
|Actual Study Completion Date :||February 2004|
- Percentage reduction in seizure frequency. [ Time Frame: 16-week treatment period ]
- To further assess safety.
- The patient-weighted Quality Of Life In Epilepsy inventory.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630968
|Study Director:||UCB Clinical Trial Call Center||+1 877 822 9493 (UCB)|